SciSparc Ltd. (NASDAQ: SPRC), a pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it has signed an agreement with the Soroka University Medical Center, located in Be'er-Sheva, Israel.

What's It About?

SciSparc, along with the Medical Center, aims to conduct a clinical study for SCI-210 in patients suffering from autism spectrum disorder (ASD).

In addition, "the trial will investigate the effect and safety of SciSparc’s drug candidate SCI-210, a proprietary combination of cannabidiol, and CannAmide, in comparison to CBD monotherapy in treating ASD," reads the press release.

“The signing of the agreement with Soroka Medical Center represents another step towards commencing our clinical trial in ASD,” said Oz Adler, SciSparc's CEO. "The trial in ASD strengthens the Company's advanced clinical programs, alongside our phase IIb clinical trial for SCI-110 in patients with Tourette Syndrome and the phase IIa …

Full story available on Benzinga.com